Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®

Core Viewpoint - Evoke Pharma has received notices of allowance for two U.S. patent applications, enhancing its intellectual property for GIMOTI® (metoclopramide) nasal spray, which is the only FDA-approved non-oral therapy for diabetic gastroparesis in the U.S. [1][2] Group 1: Patent Applications - The two patent applications, U.S. 17/366,839 and U.S. 17/366,818, focus on "Nasal Formulations of Metoclopramide," providing additional claims for intranasal administration of metoclopramide for treating gastroparesis [2] - These patents are expected to be Orange Book listable and will expire at the end of 2029, further solidifying the company's market position [2] Group 2: Product Efficacy - GIMOTI offers a reliable treatment option by bypassing the gastrointestinal tract, addressing the challenge of effective drug absorption in patients with gastroparesis [3] - The CEO of Evoke Pharma emphasized that GIMOTI is a groundbreaking therapy, with data showing that many patients find relief with this nasal spray compared to oral medications [4] Group 3: Market Context - Diabetic gastroparesis affects millions globally, leading to delayed stomach emptying and serious gastrointestinal symptoms, which can compromise the efficacy of orally administered medications [6] - Prior to GIMOTI's FDA approval, metoclopramide was only available in oral and injectable forms, making GIMOTI the only approved drug in the U.S. for treating gastroparesis [6]